10-Q: Odyssey Health Faces Severe Going Concern Doubts Amidst Mounting Losses and Suspended R&D

Odyssey Health, Inc. reported a significant net loss for the nine months ended April 30, 2025, and disclosed substantial doubt about its ability to continue as a going concern due to recurring operating losses and negative cash flows.

Summary

• Odyssey Health, Inc. reported a net loss of $1,490,775 for the nine months ended April 30, 2025, a significant decline from a net income of $11,897,190 in the prior year, primarily due to the absence of a one-time asset sale gain.
• The company generated no revenue for the three or nine months ended April 30, 2025, or 2024, as its products are still in the development stage and require FDA clearance.
• Cash on hand as of April 30, 2025, was critically low at $3,186, which is insufficient to cover operating expenses through June 12, 2026.
• Total current liabilities increased to $6,867,290 as of April 30, 2025, from $5,919,895 as of July 31, 2024, driven by increases in accounts payable, accrued wages, and accrued interest.
• The accumulated deficit worsened to $(62,493,921) as of April 30, 2025, from $(61,003,146) as of July 31, 2024.
• Research and development expenses were $0 for the nine months ended April 30, 2025, down 100% from $65,766 in the prior year, indicating a suspension of R&D activities.
• General and administrative expenses decreased by 40% to $756,676 for the nine months ended April 30, 2025, primarily due to fewer employees and lower activity.
• The company's investment in Oragenics, Inc. common stock significantly decreased in fair value to $97,149 as of April 30, 2025, from $529,203 as of July 31, 2024.
• Several promissory notes, including those with LGH Investments, LLC, an accredited investor (Jonathan Lutz), Mast Hill Fund L.P., and officers/directors, had their maturity dates extended to July 2025 or June 2025.
• The company received $300,000 from a new accredited investor promissory note in August 2024, bearing an 18% annual interest rate and maturing in August 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by critically low cash, mounting losses, increasing liabilities, and an explicit 'going concern' warning. The suspension of R&D activities further dampens future prospects, and repeated debt maturity extensions highlight ongoing liquidity challenges. While operating cash burn has reduced, it's from a very high base and the overall financial health is extremely poor.

Positives

• Net cash used in operating activities significantly decreased to $299,193 for the nine months ended April 30, 2025, from $1,151,575 in the prior year, indicating improved cash management despite ongoing losses.
• Loss from operations decreased by 64% to $(865,075) for the nine months ended April 30, 2025, compared to $(2,377,043) in the prior year, reflecting reduced operating expenses.
• Stock-based compensation and general and administrative expenses saw substantial reductions, contributing to the lower operating loss.

Negatives

• The company reported a net loss of $1,490,775 for the nine months ended April 30, 2025, a stark contrast to a net income of $11,897,190 in the comparable prior period, primarily due to the absence of a one-time asset sale gain.
• Odyssey Health has no current revenue and its products are still in development, requiring FDA clearance before commercialization.
• The company's cash balance is extremely low at $3,186, which is insufficient to meet operating expenses for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Total liabilities increased, and the accumulated deficit deepened to over $62 million, indicating a deteriorating financial position.
• The fair value of the company's investment in Oragenics, Inc. common stock declined significantly by over $432,000 during the nine-month period.
• Research and development activities have been suspended, which could hinder future product commercialization and growth.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring operating losses, negative cash flows, and insufficient working capital.
• Dependence on raising additional capital through debt, equity issuances, or collaborative arrangements, with no assurance of success or favorable terms.
• Potential for significant dilution of current stockholders' equity interests if additional equity securities are issued.
• Risk of scaling down or ceasing operations if additional financing is not obtained on a timely basis.
• Products are in development and require FDA clearance or approval, with no assurance of successful commercialization.
• Material weaknesses in internal control over financial reporting, specifically insufficient resources and inadequate segregation of duties, which could affect financial reporting reliability.
• Contingent liability of a $250,000 cash payment upon FDA clearance of the Save a Life choking rescue device, which is not yet probable.

Future Outlook

Odyssey Health expects to experience continuing operating losses and negative cash flows for the foreseeable future. The company's ability to continue as a going concern is dependent on its success in raising additional capital through debt, equity issuances, or collaborative arrangements. The company has suspended research and development activities until market conditions improve and will adjust its business plan if unable to secure necessary financing.

Management Comments

• "We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration (FDA) clearance or approval to market our products will be required to sell in the United States."
• "For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations."
• "If we are unable to raise additional capital, secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection, we will adjust our business plan."
• "We have suspended research and development activities until market conditions improve."

Industry Context

Odyssey Health operates in the medical device and product development sector, a highly regulated industry requiring significant R&D investment and regulatory approvals (e.g., FDA) before commercialization. The company's current state of suspended R&D and lack of revenue places it at a significant disadvantage compared to established players or even well-funded startups in the medical technology space. Its reliance on debt financing and inability to generate revenue from its core business indicates a struggle to progress its product pipeline, which is critical in this capital-intensive industry.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• Promissory Notes payable to officers and directors totaling $100,000 in principal and $26,843 in accrued interest as of April 30, 2025, with maturity extended to July 31, 2025.
• Amounts due to Joseph M. Redmond (CEO) for reimbursement of expenses ($19,025) and unpaid salary/bonus ($1,299,846) as of April 30, 2025.
• Amounts due to Christine M. Farrell (CFO) for reimbursement of expenses ($24,951) and unpaid salary/bonus ($460,002) as of April 30, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises and substantial risk of losing their investment due to the company's going concern issues and accumulated deficit.
• **Employees**: Accrued wages have increased, indicating potential delays or difficulties in compensation, which could impact morale and retention.
• **Creditors**: Promissory notes have been repeatedly extended, indicating the company's inability to repay debt on original terms, increasing credit risk.
• **Customers**: No products are currently being sold or marketed, so there is no direct impact on customers at this time.
• **Suppliers**: Accounts payable have increased, suggesting potential delays in payments to suppliers.

Next Steps

• Obtain additional capital through debt, equity, or collaborative arrangements to meet obligations and execute the business plan.
• Seek FDA clearance or approval for the CardioMap heart monitoring and screening device and the Save a Life choking rescue device to enable commercialization.
• Resume research and development activities once market conditions improve and sufficient capital is secured.
• Continue efforts to improve internal controls over financial reporting by using third-party specialists, increasing independent reconciliations, and potentially appointing additional outside directors and audit committee members.

Key Dates

Recommendation

Keywords

Medical Devices, Biotechnology, Research and Development, SEC Filing, 10-Q, Going Concern, Financial Reporting, Debt Financing, Product Development, CardioMap, Save a Life